A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRD

Introduction: Peritoneal dialysis (PD) shows promise for urgent-start dialysis in end-stage renal disease (ESRD), with automated PD (APD) having advantages. However, there is limited multicenter randomized controlled trial (RCT) evidence comparing APD with temporary hemodialysis (HD) for this indica...

Full description

Saved in:
Bibliographic Details
Main Authors: Haijiao Jin, Wei Fang, Ling Wang, Xiujuan Zang, Yueyi Deng, Guoqing Wu, Ying Li, Xiaonong Chen, Niansong Wang, Gengru Jiang, Zhiyong Guo, Xiaoxia Wang, Yinghui Qi, Shifan Lv, Zhaohui Ni
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:Kidney International Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924018096
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849336061752246272
author Haijiao Jin
Wei Fang
Ling Wang
Xiujuan Zang
Yueyi Deng
Guoqing Wu
Ying Li
Xiaonong Chen
Niansong Wang
Gengru Jiang
Zhiyong Guo
Xiaoxia Wang
Yinghui Qi
Shifan Lv
Zhaohui Ni
author_facet Haijiao Jin
Wei Fang
Ling Wang
Xiujuan Zang
Yueyi Deng
Guoqing Wu
Ying Li
Xiaonong Chen
Niansong Wang
Gengru Jiang
Zhiyong Guo
Xiaoxia Wang
Yinghui Qi
Shifan Lv
Zhaohui Ni
author_sort Haijiao Jin
collection DOAJ
description Introduction: Peritoneal dialysis (PD) shows promise for urgent-start dialysis in end-stage renal disease (ESRD), with automated PD (APD) having advantages. However, there is limited multicenter randomized controlled trial (RCT) evidence comparing APD with temporary hemodialysis (HD) for this indication in China. Methods: This multicenter RCT enrolled 116 patients with ESRD requiring urgent dialysis from 11 hospitals, randomized to APD or HD. Patients underwent a 2-week treatment with APD or HD via a temporary central venous catheter (CVC), followed by a maintenance PD. Outcomes were assessed over 12 months during 8 visits. The primary outcome was dialysis-related complications. Results: The 1-year incidence of dialysis-related complications was significantly lower in the APD group than in the HD group (25.9% vs. 56.9%, P = 0.001). No significant differences were found between the groups in terms of PD catheter survival rates (P = 0.388), peritonitis-free survival rates (P = 0.335), and patient survival rates (P = 0.329). In terms of health economics, the total direct medical cost of the initial hospitalization for patients with ESRD was significantly lower in the APD group (27,008.39 CNY) than in the HD group (42,597.54 CNY) (P = 0.001), whereas the duration of the first hospital stay showed no significant difference (P = 0.424). Conclusion: For patients with ESRD needing urgent initiation of dialysis, APD was associated with a lower incidence of dialysis-related complications and lower initial hospitalization costs compared with HD, with no significant differences in PD catheter survival rate, peritonitis-free survival rates, or patient survival rates. These findings can guide clinical decision-making for the optimal dialysis modality for patients requiring urgent dialysis initiation.
format Article
id doaj-art-9aa55353be414dbbaa507f6273f6d9ff
institution Kabale University
issn 2468-0249
language English
publishDate 2024-09-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj-art-9aa55353be414dbbaa507f6273f6d9ff2025-08-20T03:45:06ZengElsevierKidney International Reports2468-02492024-09-01992627263410.1016/j.ekir.2024.06.032A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRDHaijiao Jin0Wei Fang1Ling Wang2Xiujuan Zang3Yueyi Deng4Guoqing Wu5Ying Li6Xiaonong Chen7Niansong Wang8Gengru Jiang9Zhiyong Guo10Xiaoxia Wang11Yinghui Qi12Shifan Lv13Zhaohui Ni14Department of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Molecular Cell Laboratory for Kidney Disease, Shanghai, China; Shanghai Peritoneal Dialysis Research Center, Shanghai, China; Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Molecular Cell Laboratory for Kidney Disease, Shanghai, China; Shanghai Peritoneal Dialysis Research Center, Shanghai, China; Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Molecular Cell Laboratory for Kidney Disease, Shanghai, China; Shanghai Peritoneal Dialysis Research Center, Shanghai, China; Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai Songjiang District Central Hospital, Shanghai, ChinaDepartment of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Nephrology, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang ChinaDepartment of Nephrology, Central Hospital of Shanghai Jiading District, Shanghai, ChinaDepartment of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai Punan Hospital, Shanghai, ChinaDepartment of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Molecular Cell Laboratory for Kidney Disease, Shanghai, China; Shanghai Peritoneal Dialysis Research Center, Shanghai, China; Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Molecular Cell Laboratory for Kidney Disease, Shanghai, China; Shanghai Peritoneal Dialysis Research Center, Shanghai, China; Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Correspondence: Zhaohui Ni, Department of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, No. 160, Pujian Road, Shanghai 200127, China.Introduction: Peritoneal dialysis (PD) shows promise for urgent-start dialysis in end-stage renal disease (ESRD), with automated PD (APD) having advantages. However, there is limited multicenter randomized controlled trial (RCT) evidence comparing APD with temporary hemodialysis (HD) for this indication in China. Methods: This multicenter RCT enrolled 116 patients with ESRD requiring urgent dialysis from 11 hospitals, randomized to APD or HD. Patients underwent a 2-week treatment with APD or HD via a temporary central venous catheter (CVC), followed by a maintenance PD. Outcomes were assessed over 12 months during 8 visits. The primary outcome was dialysis-related complications. Results: The 1-year incidence of dialysis-related complications was significantly lower in the APD group than in the HD group (25.9% vs. 56.9%, P = 0.001). No significant differences were found between the groups in terms of PD catheter survival rates (P = 0.388), peritonitis-free survival rates (P = 0.335), and patient survival rates (P = 0.329). In terms of health economics, the total direct medical cost of the initial hospitalization for patients with ESRD was significantly lower in the APD group (27,008.39 CNY) than in the HD group (42,597.54 CNY) (P = 0.001), whereas the duration of the first hospital stay showed no significant difference (P = 0.424). Conclusion: For patients with ESRD needing urgent initiation of dialysis, APD was associated with a lower incidence of dialysis-related complications and lower initial hospitalization costs compared with HD, with no significant differences in PD catheter survival rate, peritonitis-free survival rates, or patient survival rates. These findings can guide clinical decision-making for the optimal dialysis modality for patients requiring urgent dialysis initiation.http://www.sciencedirect.com/science/article/pii/S2468024924018096automated peritoneal dialysisend-stage renal diseasehemodialysisurgent-start peritoneal dialysis
spellingShingle Haijiao Jin
Wei Fang
Ling Wang
Xiujuan Zang
Yueyi Deng
Guoqing Wu
Ying Li
Xiaonong Chen
Niansong Wang
Gengru Jiang
Zhiyong Guo
Xiaoxia Wang
Yinghui Qi
Shifan Lv
Zhaohui Ni
A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRD
Kidney International Reports
automated peritoneal dialysis
end-stage renal disease
hemodialysis
urgent-start peritoneal dialysis
title A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRD
title_full A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRD
title_fullStr A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRD
title_full_unstemmed A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRD
title_short A Randomized Controlled Trial Comparing Automated Peritoneal Dialysis and Hemodialysis for Urgent-Start Dialysis in ESRD
title_sort randomized controlled trial comparing automated peritoneal dialysis and hemodialysis for urgent start dialysis in esrd
topic automated peritoneal dialysis
end-stage renal disease
hemodialysis
urgent-start peritoneal dialysis
url http://www.sciencedirect.com/science/article/pii/S2468024924018096
work_keys_str_mv AT haijiaojin arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT weifang arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT lingwang arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT xiujuanzang arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT yueyideng arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT guoqingwu arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT yingli arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT xiaonongchen arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT niansongwang arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT gengrujiang arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT zhiyongguo arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT xiaoxiawang arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT yinghuiqi arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT shifanlv arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT zhaohuini arandomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT haijiaojin randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT weifang randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT lingwang randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT xiujuanzang randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT yueyideng randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT guoqingwu randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT yingli randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT xiaonongchen randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT niansongwang randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT gengrujiang randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT zhiyongguo randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT xiaoxiawang randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT yinghuiqi randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT shifanlv randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd
AT zhaohuini randomizedcontrolledtrialcomparingautomatedperitonealdialysisandhemodialysisforurgentstartdialysisinesrd